Xtant Medical Holdings Inc. has appointed Mark Schallenberger as chief operations officer (COO), effective Jan. 16.
 
“We are thrilled to have Mark rejoin the team as we reinvent Xtant,” Xtant Medical President/CEO Sean Browne said. “In this newly created role, Mark will drive the modernization of our production, lead the optimization of our processes and operations, and support the diversification and development of new product lines. We look forward to Mark’s contributions to our key growth pillars.”
 
Schallenberger has more than 12 years of orthobiologics experience focused on product development and scientific affairs, having most recently served as COO at Surgenex, a medical technology manufacturer, since June 2019. Previously, he served as senior director of Marketing and Product Development at DCI Donor Services Tissue Bank, beginning in February 2016. Before that, Schallenberger served in various roles with increasing responsibility from September 2010 to February 2016, culminating with director of Scientific Affairs at Xtant Medical, formerly Bacterin International Holdings. 

Schallenberger earned a master’s of science degree in chemical biology from The Scripps Research Institute and a bachelor of science degree in chemistry from the University of Montana.

“I am excited to be rejoining Xtant Medical in this new role,” Schallenberger said. “The company is well-positioned to invest and build upon the development of its innovative and industry leading orthobiologics. I look forward to working with the leadership team to drive better operational efficiencies and generate profitable growth.”
 
Xtant Medical Holdings designs, develops, and commercializes a portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures.